Evaluation of outcome measures for myasthenia gravis subgroups
•Consistency evaluation of myasthenia gravis specific scales QMG, MG-ADL, MG-QOL15r and MGC.•Exploration of effect of clinical variables have on myasthenia gravis scales.•Comparison of the scale response to disease change in different myasthenia gravis subgroups. Disease evaluation and long-term fol...
Gespeichert in:
Veröffentlicht in: | Journal of clinical neuroscience 2021-09, Vol.91, p.270-275 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 275 |
---|---|
container_issue | |
container_start_page | 270 |
container_title | Journal of clinical neuroscience |
container_volume | 91 |
creator | Luo, Yien Dong, Xiaohua Peng, Yuyao Cui, Biqi Yan, Chengkai Jin, Wanlin Li, Yi Zhou, Ran Huang, Kun Yang, Huan |
description | •Consistency evaluation of myasthenia gravis specific scales QMG, MG-ADL, MG-QOL15r and MGC.•Exploration of effect of clinical variables have on myasthenia gravis scales.•Comparison of the scale response to disease change in different myasthenia gravis subgroups.
Disease evaluation and long-term follow-up of myasthenia gravis (MG) patients rely on disease-specific measures. We evaluated four widely used MG-specific assessments, and compared the response to disease change in different MG subgroups.
We used the Cronbach's α coefficient to test reliability, Pearson correlation coefficients to test construct validity, as well as one-way ANOVA and independent-sample t-tests to access discriminant validity. Analyses of similar items between QMG and MG-ADL included paired-sample t-tests and mean score comparisons. Pearson correlation coefficients were used to describe the correlation between changes of QMG, MG-ADL, MG-QOL15r and MGC. The Wilcoxon matched-pairs signed-ranks test was performed to compare the outcomes.
872 MG patients were enrolled. QMG, MG-ADL, MG-QOL15r, and MGC all exhibited high reliability. All four scales displayed good discriminant validity according to the MGFA classification and MGC score. MG-ADL showed significant differences between patients grouped by age and gender, and MG-QOL15r showed significant differences between patients grouped by age. Analyses of similar items showed that MG-ADL achieved higher scores in bulbar items, whereas QMG produced higher scores in limb items. For patients in remission or minimal manifestation status, QMG exhibited significantly greater improvement than MG-QOL15r. In patients of MGFA I, II, III, and IV, QMG showed significantly greater improvement than MG-ADL.
Patient-reported scale is an important supplement for a given period. MG-ADL has a better response to severe disease, and MG-QOL15r is more comprehensive for patients in remission or minimal manifestation status. |
doi_str_mv | 10.1016/j.jocn.2021.07.020 |
format | Article |
fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000683571000003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0967586821003702</els_id><sourcerecordid>2560057390</sourcerecordid><originalsourceid>FETCH-LOGICAL-c333t-9c563308ea5a8c8a99ed29c5ed9b4ea9e3ffde4c444ad95275cdfe1d81ebfe1e3</originalsourceid><addsrcrecordid>eNqNkF1L7DAQhoMoun78Aa96KUh7JpmmbUAEWdRzQDg3eh2y6VSzbJs1aVf892Zd8VKcmxeG9xmGh7FzDgUHXv1ZFktvh0KA4AXUBQjYYzMuUeSikrjPZqCqOpdN1Ryx4xiXAKBKhEN2hCXWCKhm7Pp2Y1aTGZ0fMt9lfhqt7ynrycQpUMw6H7L-3cTxhQZnsudgNi5mcVo8Bz-t4yk76Mwq0tlXnrCnu9vH-d_84f_9v_nNQ24RccyVlRUiNGSkaWxjlKJWpCW1alGSUYRd11Jpy7I0rZKilrbtiLcNp0VKwhN2sbu7Dv51ojjq3kVLq5UZyE9RC1kByBoVpKrYVW3wMQbq9Dq43oR3zUFvveml3nrTW28aap28JehyB73RwnfROhosfYNJXNWgrDlsB1O7-X177sZPvXM_DWNCr3YoJVsbR0F_4a0LZEfdevfTnx9TP5cK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2560057390</pqid></control><display><type>article</type><title>Evaluation of outcome measures for myasthenia gravis subgroups</title><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Access via ScienceDirect (Elsevier)</source><creator>Luo, Yien ; Dong, Xiaohua ; Peng, Yuyao ; Cui, Biqi ; Yan, Chengkai ; Jin, Wanlin ; Li, Yi ; Zhou, Ran ; Huang, Kun ; Yang, Huan</creator><creatorcontrib>Luo, Yien ; Dong, Xiaohua ; Peng, Yuyao ; Cui, Biqi ; Yan, Chengkai ; Jin, Wanlin ; Li, Yi ; Zhou, Ran ; Huang, Kun ; Yang, Huan</creatorcontrib><description>•Consistency evaluation of myasthenia gravis specific scales QMG, MG-ADL, MG-QOL15r and MGC.•Exploration of effect of clinical variables have on myasthenia gravis scales.•Comparison of the scale response to disease change in different myasthenia gravis subgroups.
Disease evaluation and long-term follow-up of myasthenia gravis (MG) patients rely on disease-specific measures. We evaluated four widely used MG-specific assessments, and compared the response to disease change in different MG subgroups.
We used the Cronbach's α coefficient to test reliability, Pearson correlation coefficients to test construct validity, as well as one-way ANOVA and independent-sample t-tests to access discriminant validity. Analyses of similar items between QMG and MG-ADL included paired-sample t-tests and mean score comparisons. Pearson correlation coefficients were used to describe the correlation between changes of QMG, MG-ADL, MG-QOL15r and MGC. The Wilcoxon matched-pairs signed-ranks test was performed to compare the outcomes.
872 MG patients were enrolled. QMG, MG-ADL, MG-QOL15r, and MGC all exhibited high reliability. All four scales displayed good discriminant validity according to the MGFA classification and MGC score. MG-ADL showed significant differences between patients grouped by age and gender, and MG-QOL15r showed significant differences between patients grouped by age. Analyses of similar items showed that MG-ADL achieved higher scores in bulbar items, whereas QMG produced higher scores in limb items. For patients in remission or minimal manifestation status, QMG exhibited significantly greater improvement than MG-QOL15r. In patients of MGFA I, II, III, and IV, QMG showed significantly greater improvement than MG-ADL.
Patient-reported scale is an important supplement for a given period. MG-ADL has a better response to severe disease, and MG-QOL15r is more comprehensive for patients in remission or minimal manifestation status.</description><identifier>ISSN: 0967-5868</identifier><identifier>EISSN: 1532-2653</identifier><identifier>DOI: 10.1016/j.jocn.2021.07.020</identifier><identifier>PMID: 34373039</identifier><language>eng</language><publisher>OXFORD: Elsevier Ltd</publisher><subject>Clinical Neurology ; Life Sciences & Biomedicine ; MG-ADL ; MG-QOL15r ; MGC ; Myasthenia gravis ; Neurosciences ; Neurosciences & Neurology ; Outcome measure ; QMG ; Science & Technology</subject><ispartof>Journal of clinical neuroscience, 2021-09, Vol.91, p.270-275</ispartof><rights>2021 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>2</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000683571000003</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c333t-9c563308ea5a8c8a99ed29c5ed9b4ea9e3ffde4c444ad95275cdfe1d81ebfe1e3</citedby><cites>FETCH-LOGICAL-c333t-9c563308ea5a8c8a99ed29c5ed9b4ea9e3ffde4c444ad95275cdfe1d81ebfe1e3</cites><orcidid>0000-0002-8690-2544</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jocn.2021.07.020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,39265,46002</link.rule.ids></links><search><creatorcontrib>Luo, Yien</creatorcontrib><creatorcontrib>Dong, Xiaohua</creatorcontrib><creatorcontrib>Peng, Yuyao</creatorcontrib><creatorcontrib>Cui, Biqi</creatorcontrib><creatorcontrib>Yan, Chengkai</creatorcontrib><creatorcontrib>Jin, Wanlin</creatorcontrib><creatorcontrib>Li, Yi</creatorcontrib><creatorcontrib>Zhou, Ran</creatorcontrib><creatorcontrib>Huang, Kun</creatorcontrib><creatorcontrib>Yang, Huan</creatorcontrib><title>Evaluation of outcome measures for myasthenia gravis subgroups</title><title>Journal of clinical neuroscience</title><addtitle>J CLIN NEUROSCI</addtitle><description>•Consistency evaluation of myasthenia gravis specific scales QMG, MG-ADL, MG-QOL15r and MGC.•Exploration of effect of clinical variables have on myasthenia gravis scales.•Comparison of the scale response to disease change in different myasthenia gravis subgroups.
Disease evaluation and long-term follow-up of myasthenia gravis (MG) patients rely on disease-specific measures. We evaluated four widely used MG-specific assessments, and compared the response to disease change in different MG subgroups.
We used the Cronbach's α coefficient to test reliability, Pearson correlation coefficients to test construct validity, as well as one-way ANOVA and independent-sample t-tests to access discriminant validity. Analyses of similar items between QMG and MG-ADL included paired-sample t-tests and mean score comparisons. Pearson correlation coefficients were used to describe the correlation between changes of QMG, MG-ADL, MG-QOL15r and MGC. The Wilcoxon matched-pairs signed-ranks test was performed to compare the outcomes.
872 MG patients were enrolled. QMG, MG-ADL, MG-QOL15r, and MGC all exhibited high reliability. All four scales displayed good discriminant validity according to the MGFA classification and MGC score. MG-ADL showed significant differences between patients grouped by age and gender, and MG-QOL15r showed significant differences between patients grouped by age. Analyses of similar items showed that MG-ADL achieved higher scores in bulbar items, whereas QMG produced higher scores in limb items. For patients in remission or minimal manifestation status, QMG exhibited significantly greater improvement than MG-QOL15r. In patients of MGFA I, II, III, and IV, QMG showed significantly greater improvement than MG-ADL.
Patient-reported scale is an important supplement for a given period. MG-ADL has a better response to severe disease, and MG-QOL15r is more comprehensive for patients in remission or minimal manifestation status.</description><subject>Clinical Neurology</subject><subject>Life Sciences & Biomedicine</subject><subject>MG-ADL</subject><subject>MG-QOL15r</subject><subject>MGC</subject><subject>Myasthenia gravis</subject><subject>Neurosciences</subject><subject>Neurosciences & Neurology</subject><subject>Outcome measure</subject><subject>QMG</subject><subject>Science & Technology</subject><issn>0967-5868</issn><issn>1532-2653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNkF1L7DAQhoMoun78Aa96KUh7JpmmbUAEWdRzQDg3eh2y6VSzbJs1aVf892Zd8VKcmxeG9xmGh7FzDgUHXv1ZFktvh0KA4AXUBQjYYzMuUeSikrjPZqCqOpdN1Ryx4xiXAKBKhEN2hCXWCKhm7Pp2Y1aTGZ0fMt9lfhqt7ynrycQpUMw6H7L-3cTxhQZnsudgNi5mcVo8Bz-t4yk76Mwq0tlXnrCnu9vH-d_84f_9v_nNQ24RccyVlRUiNGSkaWxjlKJWpCW1alGSUYRd11Jpy7I0rZKilrbtiLcNp0VKwhN2sbu7Dv51ojjq3kVLq5UZyE9RC1kByBoVpKrYVW3wMQbq9Dq43oR3zUFvveml3nrTW28aap28JehyB73RwnfROhosfYNJXNWgrDlsB1O7-X177sZPvXM_DWNCr3YoJVsbR0F_4a0LZEfdevfTnx9TP5cK</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Luo, Yien</creator><creator>Dong, Xiaohua</creator><creator>Peng, Yuyao</creator><creator>Cui, Biqi</creator><creator>Yan, Chengkai</creator><creator>Jin, Wanlin</creator><creator>Li, Yi</creator><creator>Zhou, Ran</creator><creator>Huang, Kun</creator><creator>Yang, Huan</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8690-2544</orcidid></search><sort><creationdate>202109</creationdate><title>Evaluation of outcome measures for myasthenia gravis subgroups</title><author>Luo, Yien ; Dong, Xiaohua ; Peng, Yuyao ; Cui, Biqi ; Yan, Chengkai ; Jin, Wanlin ; Li, Yi ; Zhou, Ran ; Huang, Kun ; Yang, Huan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c333t-9c563308ea5a8c8a99ed29c5ed9b4ea9e3ffde4c444ad95275cdfe1d81ebfe1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical Neurology</topic><topic>Life Sciences & Biomedicine</topic><topic>MG-ADL</topic><topic>MG-QOL15r</topic><topic>MGC</topic><topic>Myasthenia gravis</topic><topic>Neurosciences</topic><topic>Neurosciences & Neurology</topic><topic>Outcome measure</topic><topic>QMG</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luo, Yien</creatorcontrib><creatorcontrib>Dong, Xiaohua</creatorcontrib><creatorcontrib>Peng, Yuyao</creatorcontrib><creatorcontrib>Cui, Biqi</creatorcontrib><creatorcontrib>Yan, Chengkai</creatorcontrib><creatorcontrib>Jin, Wanlin</creatorcontrib><creatorcontrib>Li, Yi</creatorcontrib><creatorcontrib>Zhou, Ran</creatorcontrib><creatorcontrib>Huang, Kun</creatorcontrib><creatorcontrib>Yang, Huan</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luo, Yien</au><au>Dong, Xiaohua</au><au>Peng, Yuyao</au><au>Cui, Biqi</au><au>Yan, Chengkai</au><au>Jin, Wanlin</au><au>Li, Yi</au><au>Zhou, Ran</au><au>Huang, Kun</au><au>Yang, Huan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of outcome measures for myasthenia gravis subgroups</atitle><jtitle>Journal of clinical neuroscience</jtitle><stitle>J CLIN NEUROSCI</stitle><date>2021-09</date><risdate>2021</risdate><volume>91</volume><spage>270</spage><epage>275</epage><pages>270-275</pages><issn>0967-5868</issn><eissn>1532-2653</eissn><abstract>•Consistency evaluation of myasthenia gravis specific scales QMG, MG-ADL, MG-QOL15r and MGC.•Exploration of effect of clinical variables have on myasthenia gravis scales.•Comparison of the scale response to disease change in different myasthenia gravis subgroups.
Disease evaluation and long-term follow-up of myasthenia gravis (MG) patients rely on disease-specific measures. We evaluated four widely used MG-specific assessments, and compared the response to disease change in different MG subgroups.
We used the Cronbach's α coefficient to test reliability, Pearson correlation coefficients to test construct validity, as well as one-way ANOVA and independent-sample t-tests to access discriminant validity. Analyses of similar items between QMG and MG-ADL included paired-sample t-tests and mean score comparisons. Pearson correlation coefficients were used to describe the correlation between changes of QMG, MG-ADL, MG-QOL15r and MGC. The Wilcoxon matched-pairs signed-ranks test was performed to compare the outcomes.
872 MG patients were enrolled. QMG, MG-ADL, MG-QOL15r, and MGC all exhibited high reliability. All four scales displayed good discriminant validity according to the MGFA classification and MGC score. MG-ADL showed significant differences between patients grouped by age and gender, and MG-QOL15r showed significant differences between patients grouped by age. Analyses of similar items showed that MG-ADL achieved higher scores in bulbar items, whereas QMG produced higher scores in limb items. For patients in remission or minimal manifestation status, QMG exhibited significantly greater improvement than MG-QOL15r. In patients of MGFA I, II, III, and IV, QMG showed significantly greater improvement than MG-ADL.
Patient-reported scale is an important supplement for a given period. MG-ADL has a better response to severe disease, and MG-QOL15r is more comprehensive for patients in remission or minimal manifestation status.</abstract><cop>OXFORD</cop><pub>Elsevier Ltd</pub><pmid>34373039</pmid><doi>10.1016/j.jocn.2021.07.020</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-8690-2544</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0967-5868 |
ispartof | Journal of clinical neuroscience, 2021-09, Vol.91, p.270-275 |
issn | 0967-5868 1532-2653 |
language | eng |
recordid | cdi_webofscience_primary_000683571000003 |
source | Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Access via ScienceDirect (Elsevier) |
subjects | Clinical Neurology Life Sciences & Biomedicine MG-ADL MG-QOL15r MGC Myasthenia gravis Neurosciences Neurosciences & Neurology Outcome measure QMG Science & Technology |
title | Evaluation of outcome measures for myasthenia gravis subgroups |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T22%3A31%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20outcome%20measures%20for%20myasthenia%20gravis%20subgroups&rft.jtitle=Journal%20of%20clinical%20neuroscience&rft.au=Luo,%20Yien&rft.date=2021-09&rft.volume=91&rft.spage=270&rft.epage=275&rft.pages=270-275&rft.issn=0967-5868&rft.eissn=1532-2653&rft_id=info:doi/10.1016/j.jocn.2021.07.020&rft_dat=%3Cproquest_webof%3E2560057390%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2560057390&rft_id=info:pmid/34373039&rft_els_id=S0967586821003702&rfr_iscdi=true |